What Gestofit Treats: Main Uses and Benefits

Gestofit is used for managing symptoms related to systemic imbalance across various therapeutic domains. Its uses commonly address conditions like the absence of menstrual periods (secondary amenorrhea) and management alongside estrogen for menopausal symptoms.

It is considered relevant in clinical settings marked by increased discomfort or tension, and helps address symptom clusters that may become intense or disruptive. The medication is often used when symptoms intensify and supportive relief is needed, such as during phases of increased distress.

“This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.”

It is applied when conditions produce significant symptomatic burden, and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Support for Fluctuating Discomfort Gestofit is generally applied in scenarios where additional management of discomfort is required to support patients through acute or recurrent episodes.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Gestofit, containing Natural Micronised Progesterone, is subject to strict population eligibility rules defined by regulatory authorities worldwide. These official rules determine who is explicitly allowed to use the medicine, who is restricted, and who is absolutely prohibited from use.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adult Women of reproductive age and postmenopausal women for approved indications, including Luteal Phase Support for fertility treatments.
Populations for whom use is contraindicated	Patients with Known or Suspected Breast Cancer or other hormone-sensitive cancers; Severe Hepatic Impairment or active liver disease; Undiagnosed Abnormal Genital Bleeding; Active or History of Thromboembolic Disorders (e.g., DVT, stroke).
Age-related eligibility rules	Pediatric Use is not established and the medicine is not indicated for children. Geriatric Use (65 years) is similarly not established.
Pregnancy and lactation eligibility	Permitted for Luteal Phase Support only; not recommended during Breastfeeding as the substance passes into milk.

Eligibility-Related Restrictions

Caution is required for patients with a history of Epilepsy, Migraine, or Depression, as well as those with Renal Insufficiency or conditions exacerbated by Fluid Retention, as stated in the product labeling. Use is contraindicated if a patient has a known Hypersensitivity to progesterone or formulation ingredients.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Natural Micronised Progesterone (Gestofit) primarily through pharmacokinetic changes that affect how the body processes the hormone. These interactions mainly involve the metabolic enzyme system, Cytochrome P450 3A4 (CYP3A4).

Interaction Type	Interacting Substances/Conditions	Official Regulatory Outcome
Metabolic Inducers	Rifampicin, Phenytoin, Carbamazepine, Phenobarbital, Efavirenz	Co-administration leads to increased clearance of progesterone and reduced plasma concentrations.
Metabolic Inhibitors	Ketoconazole	Co-administration causes reduced clearance of progesterone, resulting in increased systemic exposure (AUC and Cmax).
Herbal Product	St. John's Wort (Hypericum perforatum)	Officially documented to reduce progesterone plasma concentration via enzyme induction.
Drug–Food	Food (Oral Capsule)	Administration with food increases the rate and extent of progesterone absorption.

No mandatory timing rules for separating doses are specified in official labeling. Interaction-related caution is documented for patients with pre-existing hepatic impairment, as the metabolic risk with clearance-altering substances may be amplified due to reduced liver function. No medicinal products are explicitly labeled as formal contraindicated combinations with this progestogen.

How Gestofit Works

Gestofit (Micronised Progesterone) exerts its actions by engaging specific hormonal signaling pathways to influence key reproductive and systemic processes. Its mechanism is centered on supplementing endogenous hormone levels and acting as a receptor agonist.

---

Progesterone Receptor Activation

This domain covers the drug's fundamental activity: it binds to and activates the progesterone receptor (PR) in target cells, particularly within the uterus. This binding initiates a molecular cascade that influences gene expression and protein synthesis, effectively mimicking and supplementing the body’s natural progesterone levels to induce or modulate the resulting physiological activity.

---

Uterine Lining Transformation and Modulation

This mechanistic effect focuses on the endometrial pathway. Activation of the progesterone receptors drives the uterus lining into a secretory state while simultaneously modulating the proliferation of endometrial cells. This drives molecular changes that affect the lining's structure and biochemical environment, which influences the cellular activity associated with cyclical changes.

---

Myometrial Activity Dampening

This mechanism involves the influence of progesterone on the smooth muscle of the uterus (the myometrium). The drug dampens signaling sequences that lead to uncoordinated or excessive uterine muscle excitability and contractions. This action promotes a state of uterine quiescence, influencing the resulting activity of the muscle signaling on the surrounding environment.

How Gestofit is Used: Administration Guidelines

Gestofit, which contains Natural Micronised Progesterone, is administered via two approved routes, each with specific dosing instructions.

Administration Routes and Forms

Route	Form	Strengths	Use Principle
Oral	Soft Gelatin Capsules	100 mg, 200 mg	Used for systemic delivery in cyclic regimens.
Intravaginal	Capsules/Pessaries	200 mg	Used for local and systemic support, such as in ART cycles.

---

Standard Dosing and Schedule Patterns

The usage of Gestofit is defined by precise cycles and frequency, rather than continuous daily use.

• For Cyclic Oral Regimens: The dose is typically 200 mg once daily for 12 consecutive days of a 28-day cycle, or 400 mg once daily for 10 consecutive days in certain regimens.
• For Intravaginal Support: For luteal phase support in Assisted Reproductive Technology (ART) cycles, the total daily dose is typically 600 mg administered in three divided doses (e.g., 3 times 200 mg), continuing for a specified period, usually until the 7th to 12th week of pregnancy.

Administration Context and Special Conditions

To manage absorption and potential side effects, specific administration instructions apply:

The oral dose is generally taken once a day at bedtime. The capsule should be taken with water while in a standing position. While co-administration with food is known to increase absorption, the bedtime timing is often used to mitigate the risk of transient drowsiness. If a dose is missed, the protocol is to not take the missed dose but to resume the next dose at the usual scheduled time. Specific use rules for older adults do not mandate a dose change from the adult regimen.

Gestofit: Recent Clinical Evidence

---

Evidence Overview for Secondary Amenorrhea (Absence of Menstrual Periods)

Gestofit was studied for its role in managing secondary amenorrhea, a condition where a menstrual period is absent. Research involved short-term Randomized Controlled Trials (RCTs) focusing on premenopausal women. These studies researched the patterns of change in the uterine lining and evaluated whether a menstrual period occurred following administration. Limited information is available regarding the long-term impact on the body’s overall hormonal balance after the progesterone course is completed.

---

Evidence Overview for Managing Symptoms During Menopause

Research on the use of this agent during menopause has explored RCTs, Systematic Reviews, and Prospective Cohort Studies. Research was evaluated in healthy postmenopausal women, including those presenting with hot flushes and night sweats. Studies examined outcomes related to physical discomfort, such as monitored symptom intensity and variability. Findings were mixed across studies due to variability in design and administration routes utilized, and comparative evidence is lacking in some areas.

---

Evidence Overview for Luteal Phase Support in Reproductive Processes

The research base is composed of extensive RCTs and Meta-analyses. Research was evaluated in women undergoing Assisted Reproductive Technologies (ART). The studies monitored key high-level clinical endpoints, such as Clinical Pregnancy Rate, Ongoing Pregnancy Rate, and Live Birth Rate. Findings were mixed regarding the optimal route of administration (oral vs. vaginal), and research is ongoing. Follow-up durations were limited primarily to the first trimester.

---

Evidence Overview for Endometrial Support (Protection During HRT)

This agent was studied for its role in endometrial support in non-hysterectomized postmenopausal women who were observed in trials while receiving estrogen replacement therapy (HRT). The research involved RCTs and Prospective Studies to examine how the agent affects the uterine lining, monitoring for the prevention of specific endometrial changes and observing uterine bleeding patterns. Data for certain groups remain insufficient, particularly for women with pre-existing, non-malignant uterine pathologies.

---

Main Uncertainties and Gaps in the Research Evidence

Key research limitations across the evidence landscape include a degree of variability across studies, leading to findings being mixed. The certainty remains low for long-term health outcomes for all populations. Data for certain groups remain insufficient, particularly regarding specialized subgroups and long-term metabolic or endocrine effects.

Key Studies & References

1. PROMETRIUM (progesterone, USP) Capsules: Official FDA Label/DailyMed
2. Luteal Phase Support Using Subcutaneous Progesterone: A Systematic Review (ART/IVF Routes)
3. Progesterone Vaginal and Oral: MedlinePlus Drug Information (General Scope and Indications)

Common questions about Gestofit (FAQ)

---

Q: Does Gestofit interact with common antibiotics?

A: Certain classes of antibiotics known as enzyme inducers, such as Rifampicin, are documented in official safety information to interact with Gestofit. This interaction may potentially lead to a reduction in the concentration of progesterone in the body. Regulatory information does not cover all common antibiotics.

---

Q: Is it safe to drink alcohol while I am using Gestofit?

A: Official safety information describes the need for caution or avoidance of alcohol due to the medicine’s potential to cause drowsiness. Co-administration with alcohol has been described as potentially increasing the risk of central nervous system (CNS) effects.

---

Q: Is Gestofit available as a generic medicine?

A: Yes, the active ingredient, Natural Micronised Progesterone, is generally available in generic formulations, as referenced in official regulatory documents.

---

Q: Is a dry mouth a known side effect that happens with Gestofit?

A: Dry mouth is not typically listed among the most frequently reported adverse reactions (occurring in 1% to 10% of users). However, official documentation indicates it may be noted in less common or rare reports in product information summaries.

---

Q: Does Gestofit interact with aspirin or other blood-thinning medicines?

A: There is no specific mandatory warning against taking aspirin with Gestofit. However, regulatory warnings note that this medicine is contraindicated in patients with a history of thromboembolic disorders (blood clots), a condition often managed with blood-thinning medicines.

---

Q: How long after stopping Gestofit does it take for the substance to leave the body?

A: Official pharmacokinetics information indicates that the drug is rapidly processed by the body, with peak concentrations reached within a few hours of administration. The time it takes for the substance to completely leave the body is not specified in the regulatory patient information.

---

Q: What are the signs of an allergic reaction to Gestofit?

A: The medicine is contraindicated for known hypersensitivity to any of its components. Severe allergic reactions are rare and are described as situations that require immediate medical evaluation. Signs of a severe reaction described on the label include hives, difficulty breathing, or sudden swelling of the face, throat, or tongue.

---

Q: Does Gestofit affect the results of routine blood tests?

A: As a hormonal preparation, Gestofit may influence the results for certain laboratory tests. Official documentation indicates that it may influence the results for certain laboratory tests and alter concentrations of other hormones, such as those for thyroid or coagulation function.

---

Q: Is Gestofit considered a controlled substance or a restricted drug?

A: According to regulatory schedules, the active ingredient in Gestofit, Micronised Progesterone, is generally not classified as a controlled substance in the United States or under international drug control conventions.

---

Q: Can people with a history of heart issues safely take Gestofit?

A: Official safety information describes Gestofit as contraindicated for patients with an active or history of thromboembolic disease, such as a blood clot or stroke. Caution is mentioned in the labeling for individuals with pre-existing cardiovascular risk factors.

---

Q: Why is Gestofit sometimes called by a different chemical name?

A: The medicine is most commonly known by its generic name, Progesterone. While the full chemical designation is used in scientific contexts, the product is typically referred to on labels as Progesterone, USP, or Micronised Progesterone.

---

Q: Is it possible for Gestofit to stop working over a long period of use?

A: Regulatory research evidence indicates that certainty regarding long-term health outcomes and efficacy remains low across many indications. The official evidence overview notes that the certainty regarding continued effectiveness and safety over very long periods of use remains low.

---

Q: Does Gestofit cause problems with vision or eyesight?

A: Yes, official regulatory labeling lists visual disturbances as a rare, serious warning sign. These issues, such as sudden partial or complete loss of vision, are listed as a serious warning sign that requires immediate medical evaluation.

Gestofit (Natural Micronised Progesterone) must be stored in a manner that maintains the product's stability and prevents degradation, as required by regulatory labeling.

Storage Requirements

The product should be stored at Controlled Room Temperature (typically 20 C to 25 C or below 30 C) and kept from freezing. The container must be stored tightly closed in its original package and protected from light and excess moisture to ensure its shelf-life. It is mandatory to keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal must follow local requirements. Unused or expired Gestofit should be discarded by utilizing a drug take-back program. If this option is not available, the medication must be mixed with an undesirable substance (e.g., used coffee grounds or cat litter) and placed into a sealed container before being thrown into the household trash, as advised by official guidelines. Do not flush the product down the sink or toilet.